Sanofi-Aventis acquires marketing rights to Xyzal
This article was originally published in The Tan Sheet
Executive SummarySanofi-Aventis assumes the U.S. marketing rights to UCB's prescription allergy drug Xyzal (levocetirizine dihydrochloride), which could be a future switch candidate. Belgium-based UCB licensed the marketing rights to Sanofi as part of an accelerated plan to transition its U.S. business to a purely specialty-focused biopharmaceutical company, UCB announced Jan. 29. The firm says it will exit the primary care market March 1. However, UCB will continue to receive a percentage of Xyzal profits, according to the release. The deal comes weeks after Sanofi acquired U.S.-based Chattem with the intention of using the company to switch its prescription allergy drug Allegra (1"The Tan Sheet" Jan. 4, 2010). The French firm may have plans for Xyzal to follow a similar potential switch path. Xyzal's patent exclusivity expires in 2013 and the drug is the follow-on to cetirizine - the active ingredient in McNeil Consumer Healthcare's OTC allergy drug Zyrtec. Sanofi is expanding its OTC business through acquisitions, mergers and joint ventures, like its partnership with Minsheng Pharmaceutical Group in China (see story p. 6)
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?